+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Analgesics - Global Market Trajectory & Analytics

  • ID: 338926
  • Report
  • April 2021
  • Region: Global
  • Global Industry Analysts, Inc

FEATURED COMPANIES

  • Bayer AG
  • Eli Lilly and Company
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Novartis International AG
  • Pfizer, Inc.

Global Analgesics Market to Reach $59.2 Billion by 2026


Pain management continues to be one of the most sought-after treatment options for patients within the healthcare arena that underscores the critical significance of analgesics. Analgesics are drugs meant for pain control primarily. The drugs work on the CNS and peripheral nervous system for reducing or blocking pain sensitivity. There are also analgesics which work by preventing creation of pain mediating chemicals in the body. Widely used for treatment of mild to acute pain attributed to several medical conditions, injuries, surgeries and terminal disorders, analgesics have ruled the pain management domain for the past several decades. These medications have provided medical practitioners with an effective option to alleviate pain and help improve quality of life for patients. Amid the COVID-19 crisis, the global market for Analgesics estimated at US$45.1 Billion in the year 2020, is projected to reach a revised size of US$59.2 Billion by 2026, growing at a CAGR of 4.7% over the analysis period. Prescription, one of the segments analyzed in the report, is projected to grow at a 4.4% CAGR to reach US$37.7 Billion by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the OTC segment is readjusted to a revised 5.1% CAGR for the next 7-year period. This segment currently accounts for a 38.2% share of the global Analgesics market.

The U.S. Market is Estimated at $15.2 Billion in 2021, While China is Forecast to Reach $8.2 Billion by 2026


The Analgesics market in the U.S. is estimated at US$15.2 Billion in the year 2021. The country currently accounts for a 32.76% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$8.2 Billion in the year 2026 trailing a CAGR of 6.5% through the analysis period. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.3% and 3.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.4% CAGR while Rest of European market (as defined in the study) will reach US$8.8 Billion by the close of the analysis period.

Growth in these markets are benefiting from increasing incidence of diseases like cancer, arthritis, CVD, and also other acute and chronic diseases which causes severe pain. Cancer pain, neuropathic pain, post-operative pain, and lower back pain represent the important market segments. Increasing incidence of cancer globally is poised to be a key driving force for market growth. Further, increasing prevalence of chronic diseases has also fostered the use of pain management therapeutics. Increasing innovation in the area, owing to increased research investment by drug development companies, for advancing combination of compounds for developing new and more effective analgesics with enhanced efficacy as well as fewer side effects, is another prominent factor contributing towards market growth.

Opioids Segment to Reach $18.4 Billion by 2026


Opioid analgesic drugs represent the gold standard in pain relieving treatment of critically ill patients across disease segments, including COVID-19. Fentanyl, morphine, and hydromorphone are among the most commonly used IV opioid analgesic drugs in the ICU settings for COVID as well as non-COVID patients. Global Opioids segment is estimated at US$14.9 Billion in 2020, and is projected to reach US$18.4 Billion by 2026 reflecting a compounded annual growth rate of 3.7% over the analysis period. United States constitutes the largest regional market for Opioids segment, accounting for 29.9% of the global sales in 2020. China is poised to register the fastest compounded annual growth rate of 5.2% over the analysis period, to reach US$2.6 Billion by 2026.

Select Competitors (Total 146 Featured) -

  • Bayer AG
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Endo Pharmaceuticals, Inc.
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Novartis International AG
  • Pfizer, Inc.
  • Reckitt Benckiser Group PLC
  • Sanofi
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Bayer AG
  • Eli Lilly and Company
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Novartis International AG
  • Pfizer, Inc.
I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
  • A Prelude to Analgesics
  • Analgesics: Perfect Therapeutic Options to Solve Mild to Crippling Pain
  • Key Segments
  • Opioid Analgesics
  • Non-Opioid Analgesics
  • NSAIDs
  • Topical NSAIDs
  • Others
  • Acetaminophen
  • Adjuvant Analgesics
  • Impact of COVID-19 on Analgesics
  • NSAIDs
  • NSAIDs Tend to Decrease Effectiveness of COVID-19 Vaccines, States a Yale University Study
  • Opioid
  • Acetaminophen
  • Global Analgesics Market to Witness Rapid Growth
  • Drugs Indicated for Pain Management
  • The US and Europe Represent the Largest Regions, Asia-Pacific to Witness fastest Growth
  • Non-Opioids: Fastest Growing Category
  • Competition
  • Recent Market Activity
2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS
  • Growing Aging Population & Increasing Burden of Chronic Diseases Drives Market
  • EXHIBIT 1: Global Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
  • EXHIBIT 2: Fatalities by Heart Conditions: Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others
  • EXHIBIT 3: Rising Diabetes Prevalence Presents Opportunity for Cell Surface Markers: Number of Adults (20-79) with Diabetes (in Millions) by Region for 2017 and 2045
  • Growing Incidence of Cancer and the Associated Pain to Drive the Analgesics Market
  • EXHIBIT 4: Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
  • EXHIBIT 5: Global Number of New Cancer Cases and Cancer-related Deaths by Cancer Site for 2018
  • EXHIBIT 6: Number of New Cancer Cases and Deaths (in Million) by Region for 2018
  • Advancements in Design and Delivery of Analgesic Drugs
  • Development of Safer Opioids with More Safer Profiles
  • Drug Pipeline with Efficacious Drugs
  • OTC Analgesics Market to Witness Fastest Growth
  • Topical Analgesics Market Holds Significant Share
  • Combination Therapies Gain Prominence
  • A Few Novel Analgesic Products under Development
  • E-commerce Platforms Strengthen Pharmaceutical Distribution in Crisis Period
  • Neuropathic Pain Management: Market with High Potential
  • Migraine Market: A Core Vertical in CNS Pain Management
  • Migraine Care: Select Patent Expiries (2013-2015)
  • Reyvow, Eli Lilly's Novel Migraine Drug with the Potential to Lead the Global Migraine Medications Market
  • Three New Migraine Drugs Obtain FDA Approval
  • Eli Lilly's Emgality Receives FDA Approval
  • Increasing Cases of Peripheral Nerve Injuries Drive the Analgesics Market
4. GLOBAL MARKET PERSPECTIVE

III. MARKET ANALYSIS

UNITED STATES

CANADA

JAPAN

CHINA

EUROPE

FRANCE

GERMANY

ITALY

UNITED KINGDOM

SPAIN

RUSSIA

REST OF EUROPE

ASIA-PACIFIC

AUSTRALIA

INDIA

SOUTH KOREA

REST OF ASIA-PACIFIC

LATIN AMERICA

ARGENTINA

BRAZIL

MEXICO

REST OF LATIN AMERICA

MIDDLE EAST

IRAN

ISRAEL

SAUDI ARABIA

UNITED ARAB EMIRATES

REST OF MIDDLE EAST

AFRICA

IV. COMPETITION
  • Total Companies Profiled: 146

Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Bayer AG
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Endo Pharmaceuticals, Inc.
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Novartis International AG
  • Pfizer, Inc.
  • Reckitt Benckiser Group PLC
  • Sanofi
Note: Product cover images may vary from those shown
Adroll
adroll